Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of dapagliflozin treatment on urinary proteomic patterns in patients with type 2 diabetes
2015-000335-32Phase 4Completed
- Sponsor
- Steno Diabetes Center
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in urinary peptide patterns. Started May 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2015-000335-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000335-32.